Reports as of December 31 NuCana had cash and cash equivalents of GBP 17.2M compared to GBP 17.8 M as of September 30, 2023 and GBP 41.9 million as of December 31, 2022. NuCana continues to advance its various clinical programs and reported a net loss of GBP 7.7 M for the quarter ended December 31 as compared to a net loss of GBP 15.2 M for the quarter ended December 31 . Net loss for the year ended December 31 was GBP 27.6 M, compared to a net loss of GBP 32M for the year ended December 31… Basic and diluted loss per share was GBP 0.14 for the quarter and GBP 0.53 for the year ended December 31 as compared to GBP 0.29 per share for the comparable quarter and GBP 0.61 for the year ended December 31..
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
